#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA2028069	F	MMV: Inhibition of Plasmodium falciparum 3D7 at 2uM compound concentration.	Plasmodium falciparum	19		organism-based format	MMV Malaria Box
2.	ALA2028071	F	MMV: Inhibition of Plasmodium falciparum 3D7 (EC50).	Plasmodium falciparum	317		organism-based format	MMV Malaria Box
3.	ALA2028073	F	MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro).	Trypanosoma cruzi	400		organism-based format	MMV Malaria Box
4.	ALA2028074	F	MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro).	Trypanosoma brucei brucei	400		organism-based format	MMV Malaria Box
5.	ALA2028075	F	MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro).	Trypanosoma brucei rhodesiense	400		organism-based format	MMV Malaria Box
6.	ALA2028076	F	MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro.	Leishmania infantum	400		organism-based format	MMV Malaria Box
7.	ALA2028077	T	MMV: Cytotoxicity against human fibroblasts (MRC-5) cells.	Homo sapiens	400		cell-based format	MMV Malaria Box
8.	ALA1789905	F	NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.	Plasmodium yoelii	4,416		organism-based format	Novartis Malaria Screening
9.	ALA1040691	F	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
10.	ALA1040692	F	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614		organism-based format	Novartis Malaria Screening
11.	ALA1040693	T	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	Homo sapiens	5,614		cell-based format	Novartis Malaria Screening
12.	ALA1040694	F	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.		5,614		assay format	Novartis Malaria Screening
13.	ALA2094261	F	MMV: Screen against Mtb, single point, non replicating, at 25uM	Mycobacterium tuberculosis	399		organism-based format	MMV Malaria Box
14.	ALA2094262	F	MMV: Screen against Mtb, single point, replicating, at 25uM	Mycobacterium tuberculosis	399		organism-based format	MMV Malaria Box
15.	ALA2094263	F	MMV: CRC and MIC90 against Mtb (non replicating)	Mycobacterium tuberculosis	55		organism-based format	MMV Malaria Box
16.	ALA2094264	F	MMV: CRC and MIC90 against Mtb (replicating)	Mycobacterium tuberculosis	56		organism-based format	MMV Malaria Box
17.	ALA2094265	T	MMV: Cytotoxicity CRC and LD50 against HepG2	Homo sapiens	57		cell-based format	MMV Malaria Box
18.	ALA2363023	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box
19.	ALA2363024	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box
20.	ALA2363025	F	MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 72 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF.	Schistosoma mansoni	400		organism-based format	MMV Malaria Box